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using coplanar beams with 6 MV photons and the treatment 
was performed with DHX LINAC, VARIAN System. 
Pretreatment kV CBCT images were obtained at 1, 2 and 3 
day of irradiations set-up corrections were made before 
treatment if the translational setup error was greater than 3 
mm in any direction. Subsequently a weekly kV CBCT was 
repeated for whole duration of treatment. 
 
Results: A total of 360 CBCT scans were acquired and 
analyzed. The systemic errors results 1.26 mm (SD ± 0.177) in 
RL direction, 1.25 mm (SD ± 0.187) in SI direction and 1.8 mm 
(SD ± 0.255 in AP direction. The range of deviations were 0-9 
in RL directions, 0-5 mm in SI direction and 0-10 mm in AP 
direction. The frequencies of setup errors > 3 mm in RL 
direction was 3.9 %, in SI 8 % and AP directions 15.5 %, 
respectively. Analyzing the CBCT before set-up corrections 
the frequencies of set-up error > 3 mm were 17.8 %, 10.6 % 
and 5.6 % in AP, SI and RL respectively. After set-up errors 
corrections (corrections via couch shifts or patient 
repositioning) these rates were reduced to 13,3%, 7.2 and 2.2 
% in PA, SI and RL direction, respectively. 
 
Conclusion: The results of our study confirmed that image 
guidance with kV CBCT represents an effective tool for 
measuring set-up accuracy in the treatment of H&N cancer 
patients. This study suggested that kV CBCT once a week is 
adequate to overcome the problem of set-up errors in head 
and neck cancer treated with IMRT technique. 
 
Poster Viewing: 6: Clinical: Lung, palliation, sarcoma, 
haematology  
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Purpose or Objective: In 1998, our institute developed a 
class-solution for intensity-modulated radiotherapy (IMRT) for 
lung cancer. Clinical implementation of IMRT gradually 
started as of 2002. This retrospective study reports on 
toxicity and overall survival (OS) of non-small cell lung cancer 
(NSCLC) patients treated with curative intent using the 
described IMRT set-up. 
 
Material and Methods: Between 2002 and 2013, a total of 
434 patients with a thoracic malignancy have been treated 
with IMRT in the Radiation Oncology department of the Ghent 
University Hospital. Those with NSCLC and receiving a total 
dose of ≥60Gy with fraction size <3Gy, a total 223, were 
retrospectively reviewed and formed the basis of this 
analysis. Clinical endpoints of OS and acute and late 
pulmonary and esophageal toxicity grade ≥3 were analyzed in 
relation to chemotherapy (concomitant vs. sequential 
chemoradiotherapy (CRT) vs. no chemotherapy) and use of 
standardized dose-volume evaluation criteria. Analysis was 
performed in SPSS using Kaplan-Meier curves for survival and 
Chi-square analysis for toxicity.  
 
Results: Median follow-up time is 18 months (range 2-125). 
The table reports patient, tumor and treatment 
characteristics. OS was scored for all patients as date of 
death (N=140) or, if missing, as date of last consultation in 
our hospital (N=83). Acute and late toxicity data were 
available for 219 and 95 patients respectively. Median OS for 
the entire population was 25 months, 5 year OS 24%. OS was 
significantly better for patients treated with concomitant 
CRT than for those undergoing the sequential approach 
(median OS 30 months vs. 23; 5 years OS 32% vs. 12%) 
(p<0,05). Acute grade ≥3 pulmonary toxicity occurred in 7,8% 
of the patients, without significant difference between 
concurrent and sequential CRT. Acute grade ≥3 esophageal 
toxicity occurred in 5,5% of patients overall; and was 
significantly worse (p<0,01) in patients treated with 
concomitant CRT compared to sequential CRT: 10,4% vs. 4,3% 
respectively. Late grade ≥3 pulmonary and esophageal 
toxicity was observed in 3,3% and 0% respectively; late grade 
2 toxicity in 13,2% and 1,4% of the cases respectively. 
Although there was a trend towards reduced esophageal 
toxicity, the use of standardized dose-volume evaluation 
criteria (N=38) did not influence pulmonary (p=0.60) nor 
esophageal (p=0.08) toxicity significantly. 
 
Conclusion: In spite of the low 5-year OS in patients 
undergoing sequential CRT, the entire NSCLC population 
treated with IMRT in our institution obtained OS in line with 
that reported in the literature. IMRT further confirms the 
potential for reduced toxicity as observed in other single-
center experiences. Regardless of the lack of documented 
significant impact, we are convinced that the use of 
standardized dose-volume evaluation criteria has contributed 
to this positive outcome and is a precondition to exploit the 
full potential of IMRT in NSCLC.  
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Purpose or Objective: Respiratory movement and anatomical 
changes of the lesion during radiotherapy are the main 
causes of target missing and/or irradiation of healthy lung 
tissue. The organ motion control and the correct 
identification of target volume (TV) contribute to manage 
these issues; however, the open question is if the adaptation 
of TV during treatment leads to an increased incidence of 
recurrences in the area of target reduction. The aim of this 
study is to evaluate patients' pattern of failure distinguishing 
“marginal”, in field and out of field recurrences. 
 
Material and Methods: In this prospective study, since 2010, 
locally advanced NSCLC patients treated with 
radiochemotherapy (RCT) underwent a weekly chest-CT 
simulation during therapy. In case of tumor's shrinkage, a 
new TV was delineated and then a new treatment plan 
outlined ("replanning"). At the end of treatment, patients 
were sent to follow-up. The patterns of failure were 
classified as: in field (persistence or recurrence in TV post-
"replanning"), "marginal" (recurrence in the area of initial TV 
excluded from the post-"replanning" TV) and out of field 
(recurrence outside of initial TV). We also evaluated distant 
failure. 
 
